Dermcast host Hope Cook, PA-C, sits down with Chris Arico, MPAS, PA-C, to discuss “When Biologics Fail: Tricky Situations with Biologics for Psoriasis Patients.” The two dermatology professionals trade information on prescribing biologics, understanding biologic failures, and more importantly — how to get patients back on track. With multiple treatment options, Arico says one key …
During the first afternoon lecture, Zelma Chiesa Fuxench, MD, MSCE, an assistant professor of dermatology at the University of Pennsylvania, reviewed the currently available biologic agents for psoriasis and how to select the “right” biologic for the “right” patient. She began the lecture reiterating that using the same biologic for all patients is not the …
Biologic treatments have been used to target aberrant immune responses in many diseases including the dermatologic manifestations of psoriasis, systemic lupus erythematosus and atopic dermatitis. The use of biologics is not without hazard as these agents block immune pathways adapted to protect the host. For medical providers who prescribe these agents, there has been concern …
Faculty: Lindsay S. Ackerman, MD For the Fall Conference afternoon product theater, Dr. Lindsay Ackerman discussed Ilumya for the management of moderate to severe plaque psoriasis. She reviewed the growth of biologics in the field of psoriasis management since 2004. Dr. Ackerman encouraged providers to have a conversation with their patients in order to choose …
Psoriasis is a chronic immune-mediated inflammatory skin disease. Patient with psoriasis typically present with erythematous scaling patches and plaques on the elbows, knees, scalp and buttocks. Up to 30 percent of patients who have psoriasis will develop psoriatic arthritis. It has been found that patients who have psoriasis are at an increased risk of comorbidities …